MimeCure is a pioneering biotechnology company committed to transforming the treatment landscape for idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) through regenerative medicine. At the core of MimeCure’s mission is the belief that fibrotic lung diseases can be treated not just by slowing decline, but by repairing the damage and restoring a healthy lung environment. The company envisions a future where chronic fibrotic lung diseases are treated at their root; by restoring the lung’s natural regenerative potential. This vision drives MimeCure’s innovation from bench to bedside, ensuring that each step in development brings MC002 closer to providing meaningful outcomes for patients.

The company was founded in 2023 by Dr. Luke van der Koog (currently CEO), Prof. Dr. Erik Frijlink (currently director), Prof. Dr. Reinoud Gosens and Prof. Dr. Anika Nagelkerke, based on research that was carried out at the University of Groningen.

MC002 is MimeCure’s lead compound, based on a naturally occurring protein in the body and designed to help the lungs repair themselves. Instead of only treating symptoms, MC002 aims to support the regrowth and healing of the tiny air sacs in the lungs that are essential for breathing. MimeCure has obtained impressive preclinical results underpinning the promise of MC002 to become the world’s first true cure against fibrotic lung diseases. Currently the company is in full swing to carry out the entire package of preclinical activities that will allow for the first-in-man studies that are planned to start in Q3 2027.

Having an excellent IP position, a unique lead compound that is highly drugable, an enthusiastic experienced management, and a well-recognized business opportunity, MimeCure is ready to become the world’s leading company in pulmonary regenerative medicine.